Cell No. : Cell Name
RCB1640 : DAUDI
update : 2022/04/05
|
Comment | Burkitt's lymphoma. Sensitive to lymphokine-activated killer cells but resistant to natural killer cells. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA 85011437 prior to order. |
Comment from the depositor | |
Terms and conditions | 1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA85011437 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
ECACC
|
Year of deposit |
2000
|
Animal |
human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Race |
Negloid
|
Gender |
Male
|
Age at sampling |
16 years
|
Tissue |
blood
|
Disease name |
Burkitt's lymphoma
|
Classification |
cancer
|
History |
overseas, ECACC -> RIKEN Cell Bank
|
|
Lifespan |
infinite
|
Morphology |
lymphocyte-like
|
Cellosaurus(Expasy) |
CVCL_0008
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
Medium and additives |
|
RPMI1640 + 10% FBS
|
Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 10 split
|
SC frequency |
|
Subculture : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma |
|
(-)
|
Virus (HIV) |
|
LT 400
|
Virus (HTLV-1) |
|
(-)
|
Virus (EBV) |
|
(+)
|
Isozyme |
|
LD, NP
|
Chromosome mode |
|
46-47(50) : 46(10),48(40)
|
STR(human) |
|
OK
|
Reference information |
Reference |
6
|
User's Publication |
11
|
Reference |
5042
Haruta Y, Seon BK.
Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.
Proc Natl Acad Sci U S A
1986
83(20):7898-902
PubMed ID: 3464004
|
2417
Nilsson K, Giovanella, B C, Stehlin, J S, Klein G
Tumorigenicity of human hematopoietic cell lines in athymic nude mice.
Int J Cancer
1977
19:337-44
PubMed ID: 14896
|
1141
Ralph P, Moore, M A, Nilsson K
Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.
J Exp Med
1976
143:1528-33
PubMed ID: 1083890
|
4975
Neumann H, Klein E, Hauck-Granoth R, Yachnin S, Ben-Bassat H.
Comparative study of alkaline phosphatase activity in lymphocytes, mitogen-induced blasts, lymphoblastoid cell lines, acute myeloid leukemia, and chronic lymphatic leukemia cells.
Proc Natl Acad Sci U S A
1976
73(5):1432-6
PubMed ID: 1064015
|
971
Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.
Cancer Res
1968
28:1300-10
PubMed ID: 4174339
|
2416
Klein E, Klein G, Nadkarni, J S, Nadkarni, J J, Wigzell H, Clifford P
Surgace IgM specificity on cells derived from a Burkitt's lymphoma.
Lancet
1967
2:1068-70
PubMed ID: 4168541
|
User's Publication |
13229
Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J.
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
J Immunother Cancer
2020
PubMed ID: 32948652
|
5030
Tsukamoto M, Imai K, Ishimoto T, Komohara Y, Yamashita YI, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T, Arima K, Okabe H, Baba Y, Chikamoto A, Ishiko T, Hirota M, Baba H.
PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Cancer Sci
2019
110(1):310-320
PubMed ID: 30426611
|
10069
Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, Nakayama T, Kitada S, Kawano Y, Takahashi W, Sugimoto M, Takeya M, Fujimoto N, Oda Y, Eto M.
PD-L1 expression in papillary renal cell carcinoma.
BMC Urol
2017
17:8
PubMed ID: 28086852
|
10269
Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M.
Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages.
J Clin Exp Hematop
2017
57:15-20
PubMed ID: 28420814
|
13994
Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y.
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma
Cancer Sci
2016
107(11):1696-1704
PubMed ID: 27564404
|
14309
Ninomiya S, Kawano M, Abe T, Ishikawa T, Takahashi M, Tamura M, Takahashi Y, Nashimoto M.
Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines
PLoS One
2015
10(3):e0118631
PubMed ID: 25730316
|
13727
Goto H, Matsuda K, Srikoon P, Kariya R, Hattori S, Taura M, Katano H, Okada S.
Potent antitumor activity of zoledronic acid-induced Vγ9Vδ2 T cells against primary effusion lymphoma
Cancer Lett
2013
331(2):174-82
PubMed ID: 23321500
|
15339
Bai B, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Takeya M, Komohara Y.
Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study
J Clin Exp Hematop
2013
53(2):127-33
PubMed ID: 23995109
|
16574
Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.
Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain
Cytotherapy
2013
15(4):481-91
PubMed ID: 23391461
|
2320
Kim C, Matsumura M, Saijo K, Ohno T.
In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.
Cancer Immunol Immunother.
1998
47(2):90-6
PubMed ID: 9769117
|
2318
Liu SQ, Kawai K, Shiraiwa H, Hayashi H, Akaza H, Hashizaki K, Shiba R, Saijo K, Ohno T.
High rate of induction of human autologous cytotoxic T lymphocytes against renal carcinoma cells cultured with an interleukin cocktail.
Jpn J Cancer Res
1998
89(11):1195-201
PubMed ID: 9914789
|